Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 132
- Registration Number
- NCT05910034
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 233
- Registration Number
- NCT05904379
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1736
- Registration Number
- NCT05901428
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1406
- Registration Number
- NCT05883852
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 150
- Registration Number
- NCT05848011
- Locations
- 🇺🇸
United Medical Group, Miami, Florida, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 880
- Registration Number
- NCT05838066
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
- Conditions
- Clinical Stage II Gastric Cancer AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage I Gastric Cancer AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Biological: AtezolizumabProcedure: Biospecimen CollectionDrug: CapecitabineProcedure: Computed TomographyDrug: DocetaxelProcedure: EchocardiographyDrug: FluorouracilDrug: Leucovorin CalciumProcedure: LymphadenectomyProcedure: Magnetic Resonance ImagingDrug: OxaliplatinProcedure: Positron Emission TomographyProcedure: Surgical Procedure
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 240
- Registration Number
- NCT05836584
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Kaiser Permanente Dublin, Dublin, California, United States
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.